Global $6.13 Billion CAR-T Cell Therapy Markets, 2017-2020 & 2021-2026: Focus on Yescarta, Kymriah, Tecartus, Breyanzi, Abecma, Others
September 28, 2021 04:28 ET
|
Research and Markets
Dublin, Sept. 28, 2021 (GLOBE NEWSWIRE) -- The "Global CAR-T Cell Therapy Markets, Competition Forecast & Opportunities, 2021-2026" report has been added to ResearchAndMarkets.com's offering. ...
Global $15.1 Bn Immuno-oncology Clinical Trials Market to 2028
July 30, 2021 07:23 ET
|
Research and Markets
Dublin, July 30, 2021 (GLOBE NEWSWIRE) -- The "Immuno-oncology Clinical Trials Market Size, Share & Trends Analysis Report by Phase (Phase I, Phase II, Phase III, Phase IV), by Design...
Autolus Therapeutics to Report Second Quarter 2021 Financial Results on August 5, 2021, and will Participate in the William Blair Biotech Focus Conference 2021 on July 14, 2021
July 08, 2021 07:00 ET
|
Autolus Therapeutics plc
LONDON, July 08, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics Announces an Additional Nature Publication for AUTO1
May 25, 2021 07:00 ET
|
Autolus Therapeutics plc
LONDON, May 25, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced a...
Global Immuno-Oncology Assays Market (2021 to 2026) - Growing Significance of Companion Diagnostics Presents Opportunities
May 14, 2021 05:23 ET
|
Research and Markets
Dublin, May 14, 2021 (GLOBE NEWSWIRE) -- The "Immuno-Oncology Assays Market by Product & Service (Consumables, Instruments, Software), Technology (PCR, NGS, Immunoassay), Cancer Indications...
Autolus Therapeutics announces appointment of Martin Murphy as Non-executive Chairman
April 19, 2021 07:00 ET
|
Autolus Therapeutics plc
LONDON, April 19, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Global Immuno-Oncology Market Report 2021-2026: Merck's Keytruda (Pembrolizumab) Leads the Market
March 29, 2021 06:53 ET
|
Research and Markets
Dublin, March 29, 2021 (GLOBE NEWSWIRE) -- The "Immuno-Oncology - Market Analysis, Trends, Opportunities and Unmet Needs - Thematic Research" report has been added to ResearchAndMarkets.com's...
Autolus Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Progress
March 04, 2021 07:00 ET
|
Autolus Therapeutics plc
LONDON, March 04, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
February 24, 2021 07:00 ET
|
Autolus Therapeutics plc
LONDON, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
I-O Therapy Combinations Spurring Growth of the Global Immuno-oncology Market, 2020 Report - Upcoming Product Launches in Adoptive Cell Therapy Segment Hold Future Growth Potential
February 17, 2021 08:38 ET
|
Research and Markets
Dublin, Feb. 17, 2021 (GLOBE NEWSWIRE) -- The "I-O Therapy Combinations Spurring Growth of the Global Immuno-oncology Market" report has been added to ResearchAndMarkets.com's offering. This...